Christopher Sweeney, MD, MBBS, gives an overview of the most promising research into novel treatments for metastatic castration-resistant prostate cancer (mCRPC), focusing on phosphatidylinositol 3-kinase (PI3Kinase)/Akt inhibition, Poly ADP-ribose polymerase (PARP) inhibitors, and lutetium-labeled prostate-specific membrane antigen (Lu-PSMA). He emphasizes the importance of careful patient selection for these therapies, and suggests that future studies should focus on combination therapies and avoid duplicative research.Read More
Christopher J. Sweeney, MBBS
Dr. Sweeney is a Medical Oncologist at the Dana-Farber Cancer Institute (MA, USA) and Professor of Medicine at Harvard Medical School. He received his medical degree from the University of Adelaide (Australia) and completed an internship at the Royal Adelaide Hospital (Australia). Dr. Sweeney did his residency in internal medicine at Gundersen Lutheran Medical Center (WI, USA) and a fellowship in hematology/oncology at Indiana University Medical Center (IN, USA), where he was later appointed Associate Director for Clinical Research for the Simon Cancer Center. Dr. Sweeney joined the Lank Center for Genitourinary Oncology at DFCI and Harvard Medical School (MA, USA) in 2009. His primary research interest is drug discovery and development. His academic focus is primarily on the management of genitourinary malignancies, with a focus on prostate and testicular cancer.
Articles by Christopher J. Sweeney, MBBS
Update on the ARCHES Trial: New Indication for Enzalutamide in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Posted by Christopher J. Sweeney, MBBS | Dec 2019
Christopher J. Sweeney, MBBS, gives an overview of the ENZAMET study, a companion to the ARCHES trial, the latter of which demonstrated a survival benefit in all versions of mHSPC (metastatic hormone-sensitive prostate cancer) with the use of enzalutamide. Dr. Sweeney discusses how ENZAMET builds on the research conducted with ARCHES, the differences between enzalutamide and chemotherapy for high-burden, rapidly progressing disease, and why monotherapy should be phased out for PCa treatment in most patients.Read More